Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001237888 | SCV001410674 | likely benign | not provided | 2024-02-07 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001237888 | SCV004167759 | uncertain significance | not provided | 2023-04-17 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ce |
RCV001237888 | SCV004698334 | likely benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | ADGRV1: BP4 |
Ambry Genetics | RCV004609695 | SCV005109546 | uncertain significance | Inborn genetic diseases | 2024-05-02 | criteria provided, single submitter | clinical testing | The c.15884A>T (p.E5295V) alteration is located in exon 74 (coding exon 74) of the ADGRV1 gene. This alteration results from a A to T substitution at nucleotide position 15884, causing the glutamic acid (E) at amino acid position 5295 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |